优化新生儿阿片戒断综合征的药物治疗(OPTimize NOW):一项基于症状给药方法的多中心整群交叉设计随机对照试验研究方案
本研究为正在进行的多中心两阶段整群交叉随机对照试验,在美国24个站点按站点随机分组,比较基于症状的阿片类药物给药与传统计划性阿片递减对新生儿阿片戒断综合征短期结局的影响,计划纳入至少480名婴儿,假设基于症状给药可安全缩短医疗准备出院时间。
要点
- 试验在美国24个站点开展,按站点随机分为两种给药顺序,并按ESC或常规护理分层后独立随机。
- 计划纳入至少480名婴儿,在豁免知情同意下收集住院及短期结局数据。
- 研究假设基于症状给药可安全缩短患儿达到医疗准备出院的时间。
核心结论
- 该试验旨在确立基于症状的阿片类药物治疗对新生儿阿片戒断综合征的疗效、安全性和可推广性。
研究设计与样本
- 正在进行的多中心两阶段整群交叉随机对照试验,美国24个站点按站点随机分为两种序列,随机前按护理方法(ESC vs 常规护理)分层并独立随机。
- 计划纳入至少480名婴儿,在豁免知情同意下收集住院及短期结局数据。
主要发现
- 质量改进项目提示,对接受药物治疗的新生儿阿片戒断综合征患儿,基于症状(即按需、PRN、及时)的阿片给药相比计划性阿片递减可缩短住院时间并减少出生后阿片暴露。
- 这些质量改进项目结果是否可推广尚不清楚,该方案在多样化人群中的安全性所知甚少。
局限性
- 原文指出质量改进项目结果的可推广性尚不清楚。
- 原文指出该方案在多样化人群中的安全性所知甚少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioid use and misuse during pregnancy rose from 1.5 to 6.5 per 1000 deliveries between 1999 and 2014 and continues as a significant public health concern. A fivefold increase in neonatal opioid withdrawal syndrome (NOWS) has accompanied the increase in opioid use. The Eating, Sleeping, Consoling care approach (ESC) has been shown to improve outcomes for infants with NOWS and is quickly becoming the standard of care for infants affected by opioid use disorder. Quality improvement initiatives following the implementation of ESC provide some evidence to suggest that symptom-based (i.e., as needed, PRN, just in time) dosing of opioid medications for infants with significant withdrawal may be an effective alternative to using a traditional scheduled opioid taper approach. These initiatives have shown reduced length of hospital stay and decreased postnatal opioid exposure when compared to scheduled opioid dosing for infants with NOWS who receive pharmacologic treatment. It is unknown if the findings from these quality improvement initiatives are generalizable, and little is known about the safety of this approach in a diverse population. The purpose of this manuscript is to describe the design and rationale for an ongoing study to evaluate the effect of symptom-based opioid dosing compared to traditional scheduled opioid taper on short-term outcomes for infants with NOWS. METHODS/DESIGN: In this ongoing multi-center two-period cluster crossover randomized controlled trial, 24 sites within the USA were randomized at the site level into one of two sequences. Prior to randomization, sites were stratified by care approach used (ESC vs. usual care) and these strata were independently randomized. All study sites will provide care based on their random allocation. Data will be collected under waiver of consent for in-hospital and short-term outcomes for eligible infants. A minimum of 480 infants will be enrolled. We hypothesize that use of symptom-based dosing will safely reduce the length of time until infants with NOWS and at risk for pharmacological treatment are medically ready for discharge when compared to infants treated with a scheduled opioid taper. DISCUSSION: This trial is uniquely and efficiently designed to establish the efficacy, safety, and generalizability of the symptom-based dosing approach to opioid treatment for NOWS. TRIAL REGISTRATION: NCT05980260 ; registered July 27, 2023.
引用
- Young LW, Babineau DC, Das A, et al. Optimizing pharmacologic treatment for neonatal opioid withdrawal syndrome (OPTimize NOW): a symptom-based dosing approach study protocol for a multi-center, cluster crossover design randomized controlled trial. Trials. 2025. PMID: 40866977. doi:10.1186/s13063-025-09035-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。